Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2210368 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Macrophage-targeting combination therapy enhances T-DXd-induced tumor regression.
Int Immunopharmacol
March 2025
College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, Henan, China. Electronic address:
Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic approach for HER2-positive cancers, with trastuzumab deruxtecan (T-DXd) demonstrating significant efficacy. However, resistance mechanisms often limit the effectiveness of ADC monotherapy. This study explores the potential of combining T-DXd with macrophage-targeting therapies, specifically anti-SIRPα antibodies and PI3Kγ inhibitors, to enhance anti-tumor immunity.
View Article and Find Full Text PDFA Systematic Review of Mechanisms, Incidence, and Management of Trastuzumab Deruxtecan Induced ILD/Pneumonitis in Solid Tumors.
Drug Des Devel Ther
March 2025
Department of Pharmacy, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China.
Trastuzumab deruxtecan (T-DXd) has been approved to treat various tumors. While most adverse events (AEs) associated with T-DXd are manageable, interstitial lung disease (ILD)/pneumonitis is a notable AE of special concern. This review describes the incidence, severity, and management of T-DXd-induced ILD/pneumonitis across different tumors.
View Article and Find Full Text PDFPatterns of HER2 expression and genomic correlates in lung cancer, with a focus on preanalytical variables impacting immunohistochemical staining results.
J Clin Pathol
March 2025
Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Aims: Fam-trastuzumab deruxtecan-nxki (T-DXd) was recently approved for advanced stage or metastatic solid tumours with human epidermal growth factor receptor 2 (HER2) immunohistochemical (IHC) 3+ staining. Data on HER2 IHC testing and knowledge of genomic correlates in lung cancer are scarce. This study analyses genomic characteristics of HER2-expressing tumours and addresses issues with preanalytical variables for lung cancer specimens.
View Article and Find Full Text PDFDevelopment of Antibody-Drug Conjugates for Malignancies of the Uterine Corpus: A Review.
Cells
February 2025
Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
Despite recent advances in cancer treatment, the prognosis for uterine malignancies (carcinoma and sarcoma) requires further improvement. Antibody-drug conjugates (ADCs) have emerged as a novel class of anti-cancer therapeutic agents, and multiple ADCs have been approved for other types of cancer. In 2024, trastuzumab deruxtecan received approval from the US Food and Drug Administration for cancer types and became the first ADC approved for the treatment of uterine malignancies.
View Article and Find Full Text PDFTrastuzumab deruxtecan (T-DXd) is approved for HER2-low (HER2 immunohistochemistry (IHC)1+ or 2+ with non-amplified in situ hybridization (ISH)), but not HER2-0 (IHC 0) metastatic breast cancer. The impact of repeat biopsies (Bxs) in identifying new potential candidates with triple negative breast cancer (TNBC) for T-DXd treatment remains unknown. 512 consecutive patients with TNBC at diagnosis were included in the study cohort.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!